S4 Table. Univariate and multivariate analyses of factors predictive of overall survival (OS) and progression-free survival (PFS) among patients who received postoperative radiotherapy

Characteristics	OS				PFS			
	Univariate		Multivariate		Univariate		Multivariate	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (yr)								
≥ 47 (vs. < 47)	0.73 (0.45-1.19)	0.208	-	-	0.77 (0.56-1.05)	0.101	0.77 (0.54-1.09)	0.134
Clinical T category								
T3/4 (vs. T1/2)	2.28 (1.39-3.74)	0.001	2.22 (1.35-3.66)	0.002	1.89 (1.37-2.61)	< 0.001	1.82 (1.30-2.54)	< 0.001
Clinical N category								
N0/1 (vs. N2/3)	0.90 (0.54-1.49)	0.681	-	-	0.62 (0.44-0.88)	0.008	-	-
Metastatic site								
Bone and others (vs. bone only)	1.84 (0.88-3.85)	0.105	-	-	1.54 (0.96-2.47)	0.071	-	-
Others (vs. bone only)	1.31 (0.76-2.27)	0.330	-	-	1.07 (0.75-1.52)	0.710	-	-
Metastatic burden								
Single (vs. disseminated)	0.72 (0.35-1.48)	0.371	-	-	0.58 (0.38-0.91)	0.017	-	-
Oligo (vs. disseminated)	1.16 (0.60-2.23)	0.669	-	-	0.79 (0.52-1.20)	0.264	-	-
No. of metastases								
> 5 (vs. ≤ 5)	1.19 (0.67-2.12)	0.554	-	-	1.60 (1.11-2.30)	0.012	1.88 (1.29-2.75)	0.001
IHC subtypes								
Luminal A (vs. triple-negative)	0.43 (0.21-0.86)	0.018	0.39 (0.19-0.78)	0.008	0.61 (0.37-1.00)	0.051	0.51 (0.30-0.84)	0.009
Luminal B (vs. triple-negative)	0.41 (0.18-0.96)	0.041	0.37 (0.16-0.86)	0.021	0.62 (0.35-1.10)	0.104	0.48 (0.26-0.86)	0.014
HER2-enriched (vs. triple-negative)	0.37 (0.15-0.91)	0.031	0.35 (0.14-0.87)	0.023	0.57 (0.30-1.06)	0.073	0.50 (0.27-0.93)	0.031

Chemotherapy								
Preoperative (vs. both)	0.80 (0.45-1.43)	0.457	-	-	0.79 (0.55-1.13)	0.199	-	-
Postoperative (vs. both)	1.17 (0.59-2.30)	0.654	-	-	0.61 (0.36-1.02)	0.057	-	-
None (vs. both)	1.08 (0.25-4.67)	0.919	-	-	0.57 (0.20-1.58)	0.278	-	-
Type of PTR								
Mastectomy (vs. breast-conserving)	1.86 (1.09-3.16)	0.023			1.41 (1.01-1.96)	0.041	-	-
Interventions to all metastases								
Yes (vs. no)	1.16 (0.71-1.89)	0.547			0.81 (0.58-1.12)	0.198	-	-

CI, confidence interval; HER2, human epidermal growth factor 2; HR, hazard ratio; IHC, immunohistochemistry; PTR, primary tumor resection.